Infection and Chemotherapy最新文献

{"title":"Use of a Real-Time Locating System in Infection Control.","authors":"Min Hyung Kim, Yoon Soo Park","doi":"10.3947/ic.2024.0043","DOIUrl":"10.3947/ic.2024.0043","url":null,"abstract":"<p><p>Real-Time Locating Systems (RTLS) have emerged as powerful tools for revolutionizing healthcare by improving patient safety, optimizing workflow efficiency, and enhancing resource management. From patient tracking to infection control and emergency response, RTLS offer a plethora of applications. Although challenges such as privacy and integration need to be addressed, the benefits of RTLS in healthcare remain undeniable. As technology continues to evolve, the future holds exciting possibilities for RTLS, paving the way for smarter, more efficient, and patient-centered care.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"427-431"},"PeriodicalIF":2.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704862/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142480456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and Microbiological Characteristics of ST72 Methicillin-Susceptible <i>Staphylococcus aureus</i>: Comparison with ST72 Methicillin-Resistant <i>S. aureus</i>.","authors":"Jaijun Han, Euijin Chang, Jiwon Jung, Min Jae Kim, Yong Pil Chong, Sung-Han Kim, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Seongman Bae","doi":"10.3947/ic.2024.0031","DOIUrl":"10.3947/ic.2024.0031","url":null,"abstract":"<p><strong>Background: </strong>Sequence type 72 (ST72) is the predominant community-associated methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) genotype in Korea. With an increasing prevalence of the ST72 <i>S. aureus</i> lineage, regardless of methicillin resistance, it is crucial to understand the clinical and microbiological characteristics of ST72 methicillin-susceptible <i>S. aureus</i> (MSSA) as well as ST72 MRSA.</p><p><strong>Materials and methods: </strong>In this retrospective cohort study, data from patients with <i>S. aureus</i> bacteremia (SAB) who were admitted to a tertiary hospital in Korea from March 2007 to December 2018 were collected. Multilocus sequence typing was used to identify ST72 isolates. The clinical and microbiological characteristics of ST72 MSSA were compared with those of ST72 MRSA among patients infected with SAB.</p><p><strong>Results: </strong>Among the 442 SAB patients with ST72, 157 (35.5%) were infected with MSSA and 285 (64.5%) were infected with MRSA. There was a significant increase in the proportion of ST72 MSSA in both the community and hospital settings. Compared to ST72 MRSA, ST72 MSSA isolates were less likely to have multidrug resistance. The main infection foci, infection severity, and duration of bacteremia did not differ significantly between the two groups. The 90-day recurrence rate was significantly lower in the MSSA group (2.5% <i>vs.</i> 8.4%, <i>P</i>=0.03), while the 90-day mortality rate was comparable (28.0% <i>vs.</i> 23.9%, <i>P</i>=0.40).</p><p><strong>Conclusion: </strong>ST72 MSSA had similar clinical features as ST72 MRSA in terms of infection site, severity, and 90-day mortality. Despite exhibiting lower levels of antibiotic resistance, ST72 MSSA has increased in the hospital environment concurrently with ST72 MRSA.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"473-482"},"PeriodicalIF":2.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704857/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142480453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of Incident Hepatitis C Virus Infection among People Living with HIV in a HIV Clinic in Korea.","authors":"BumSik Chin, Yeonjae Kim, Gayeon Kim, Jaehyun Jeon, Min-Kyung Kim, Jae Yoon Jeong, Hyeokchoon Kwon, Seongwoo Nam","doi":"10.3947/ic.2024.0133","DOIUrl":"https://doi.org/10.3947/ic.2024.0133","url":null,"abstract":"<p><strong>Background: </strong>Coinfection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) can cause more rapid progression to cirrhosis than HCV-monoinfection. In this study, incident HCV case (IHCV)s were investigated in a HIV clinic in Korea.</p><p><strong>Materials and methods: </strong>A retrospective HIV cohort was constructed who visited National Medical Center in Korea from 2013 to 2022 and performed ≥ 1 anti-HCV antibody tests (anti-HCV) during the study period. IHCV was defined as newly confirmed HCV infection by PCR with a prior negative anti-HCV and factors associated with IHCV were investigated among alanine aminotransferase (ALT) >150 IU/mL sub-cohort without plausible reasons for ALT elevation.</p><p><strong>Results: </strong>Overall, 2,567 HIV clinic visitors were recruited during the study period and 42 (1.63%) were confirmed as HIV/HCV co-infection. Fifteen IHCVs were identified during the study period. While no IHCV was observed in 2013-2015, incidence of 2016-2019 and 2020-2022 were 0.84 and 1.48 per 1000 person-year, respectively. Subtype 1a were more common among IHCVs in 2020-2022 (8/9) while subtype 2 dominated in 2016-2019 (5/6, <i>P</i>=0.003). Most IHCVs were identified during the evaluation of de novo liver enzyme elevation which was identified through the regularly performed blood tests (86.7%, 13/15). Comparing twelve IHCVs with ALT>150 IU/mL with 58 HIV mono-infection comparators whose peak ALT exceeded 150 IU/mL during the study period, age, sex, HIV/HCV infection risk factor, CD4 cell count, and HIV-RNA viral load were not different between two groups. However, mean peak ALT of IHCVs was higher than comparators (776 <i>vs.</i> 237, <i>P</i><0.001) and syphilis treatment within prior 24 months of ALT elevation was more common in IHCV group (41.7% <i>vs.</i> 12.7%, <i>P</i>=0.026).</p><p><strong>Conclusion: </strong>Incidence rate of HCV among PLH revealed increasing trend between 2013 and 2022 among visitors at a HIV clinic in Korea. Subtype 1a dominated among IHCVs after 2020 and recent syphilis treatment was associated with IHCVs.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"56 4","pages":"544-550"},"PeriodicalIF":2.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142958546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply: Response to Nationwide Analysis of Antimicrobial Prescription in Korean Hospitals between 2018 and 2021: The 2023 KONAS Report.","authors":"I Ji Yun, Hyo Jung Park, Jungmi Chae, Yong Chan Kim, Bongyoung Kim, Jun Yong Choi","doi":"10.3947/ic.2024.0109","DOIUrl":"https://doi.org/10.3947/ic.2024.0109","url":null,"abstract":"","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"56 4","pages":"557-558"},"PeriodicalIF":2.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142958606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 Vaccination Recommendations for 2024-2025 in Korea.","authors":"Wan Beom Park, Young Hoon Hwang, Ki Tae Kwon, Ji Yun Noh, Sun Hee Park, Joon Young Song, Eun Ju Choo, Min Joo Choi, Jun Yong Choi, Jung Yeon Heo, Won Suk Choi","doi":"10.3947/ic.2024.0142","DOIUrl":"https://doi.org/10.3947/ic.2024.0142","url":null,"abstract":"<p><p>The Korean Society of Infectious Diseases has been regularly publishing guidelines for adult immunization since 2007. Following the release of coronavirus disease 2019 (COVID-19) vaccination recommendations in 2023, significant changes have occurred due to the emergence of new variant strains and the waning immunity from previous vaccinations. This article provides a comprehensive update as of November 2024, incorporating the latest evidence and guidelines. Focusing on the 2024-2025 season, this article reviews vaccines currently authorized in Korea and assesses their effectiveness against the predominant JN.1 lineage variants. The updated recommendations prioritize high-risk groups, including adults aged 65 and older, individuals with underlying medical conditions, residents of facilities vulnerable to infection, pregnant women, and healthcare workers, for vaccination with updated vaccines targeting the JN.1 strain. Additionally, COVID-19 vaccination is available for all individuals aged 6 months and older. For most adults, a single-dose strategy is emphasized, while tailored schedules may be recommended for immunocompromised individuals. This update aims to optimize vaccination strategies in Korea to ensure comprehensive protection for high-risk populations.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"56 4","pages":"453-460"},"PeriodicalIF":2.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142958555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Historical Overview of Tsutsugamushi Disease in Japan before World War II.","authors":"Moon-Hyun Chung, Jae-Seung Kang, Jin-Soo Lee","doi":"10.3947/ic.2024.0095","DOIUrl":"https://doi.org/10.3947/ic.2024.0095","url":null,"abstract":"<p><p>Tsutsugamushi disease is a febrile mite-borne disease caused by <i>Orientia tsutsugamushi</i>. Before 1945, this disease had been prevalent in Niigata, Akita, and Yamagata prefectures for centuries, occurring in areas along major rivers in these prefectures every summer about a month after floods. The patients affected were farmers, possibly new settlers on reclaimed lands, who contracted the disease following bites of tiny red bugs. From the perspective of Western medicine, the disease was first identified by Nagino, Palm, Baelz, and Kawakami in 1878-79. In 1888, the Niigata Prefectural Government mandated the reporting of tsutsugamushi disease cases. In 1892, Tanaka associated the disease and eschars with mite bites. In 1917, Kitashima, Miyajima, and Okumura confirmed its transmission only by larval mites. Ishiwara and Ogata successfully maintained the bacteria in the laboratory through serial intratesticular passage in rabbits starting in 1927. In 1930-31, the causative organism was identified by Nagayo (<i>Rickettsia orientalis</i>), Ogata (<i>R. tsutsugamushi</i>), and Kawamura (\"<i>R. akamushi</i>\"). From 1932 onwards, the incidence of the disease began to decline slowly, possibly due to reduced human activity in riverside areas.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"56 4","pages":"440-452"},"PeriodicalIF":2.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704863/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142958484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply: How Can Chronic COVID (Long-COVID Syndrome) Be Diagnosed and Treated?","authors":"Jun-Won Seo, Joon Young Song","doi":"10.3947/ic.2024.0134","DOIUrl":"https://doi.org/10.3947/ic.2024.0134","url":null,"abstract":"","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"56 4","pages":"561-563"},"PeriodicalIF":2.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142958588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quinolone Use during the First Trimester of Pregnancy and the Risk of Atopic Dermatitis, Asthma, and Allergies of Offspring during 2011 to 2020.","authors":"Jungmi Chae, Yeon-Mi Choi, Yong Chan Kim, Dong-Sook Kim","doi":"10.3947/ic.2024.0030","DOIUrl":"10.3947/ic.2024.0030","url":null,"abstract":"<p><strong>Background: </strong>Many pregnant women receive antibiotic treatment for infections. We investigated the association between quinolone use in the first trimester of pregnancy and the risk of adverse health outcomes for the child in Korea.</p><p><strong>Materials and methods: </strong>This nationwide, population-based cohort study used data on mother-child pairs from the National Health Insurance claims database. This study cohort included 2,177,765 pregnancies from January 1, 2011, to December 31, 2020, and 87,456 women were prescribed quinolones during pregnancy. After propensity score matching, the final number of study subjects was 84,365 for both quinolone and non-antibiotic users. We examined the subjects' exposure to quinolone antibiotics. The main outcome measures were absolute and relative risks of atopic dermatitis, asthma, and allergies. We adjusted for potential confounders.</p><p><strong>Results: </strong>Quinolones were prescribed at least once during the first trimester in 4.01% of pregnancies. Quinolone users had significantly higher absolute risks than non-antibiotic users for atopic dermatitis, asthma, and allergies, with significantly elevated risk ratios (RRs) for these conditions (atopic dermatitis: RR, 1.09; 95% confidence interval [CI], 1.08-1.11, asthma: RR, 1.04; 95% CI, 1.03-1.05, and allergies: RR, 1.10; 95% CI, 1.08-1.13).</p><p><strong>Conclusion: </strong>We found that quinolone exposure during the first trimester of pregnancy increased the risk of atopic dermatitis, asthma, and allergies. This study could provide physicians with useful information when selecting antibiotics for pregnant women.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"461-472"},"PeriodicalIF":2.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704861/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142480455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Opportunistic Infections in HIV-Infected Children on Treatment in Southern Morocco: A 12-Years Retrospective Follow-up Study.","authors":"Hayat Iziki, Souad Yakini, Raja Ouabich, Abdelaaziz Bounabe, Nezha Doukkani, Naima Ben-Abjaou, Sanae Ben Taleb, Hicham Blaak, Amal Boutib, Amina Barkat","doi":"10.3947/ic.2024.0056","DOIUrl":"10.3947/ic.2024.0056","url":null,"abstract":"<p><strong>Background: </strong>Human immunodeficiency virus (HIV) infection in children is a significant public health concern, increasing the risk of infant mortality. Immunodeficiency caused by HIV favors the development of opportunistic infections (OIs), which are responsible for over 90% of HIV-related deaths. This study seeks to determine the primary OIs in children with HIV followed at the Hassan II Regional Hospital Center in Sous Massa, during the period from 2012 to 2023.</p><p><strong>Materials and methods: </strong>This retrospective study is the first in Morocco to investigate OIs among HIV-infected children. It analyzed 76 complete medical records, using a data collection form designed based on existing literature.</p><p><strong>Results: </strong>This study revealed that 37% of participants were suffering from OIs, mainly diarrhea (11%), tuberculosis (9%) and pneumonia (7%).There was a significant correlation between OIs and HIV clinical stage (<i>P=</i>0.001), age (<i>P</i>=0.007), and anemia (<i>P</i>=0.001). Despite progress in management, the presence of OIs remains a risk factor for infant morbidity and mortality.</p><p><strong>Conclusion: </strong>The study highlights the importance of early detection, prevention, and adherence to treatment in reducing this burden. Management of anemia is essential.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"56 3","pages":"361-368"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11458494/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142382334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Serum miR-361-3p Predicts Early Postdischarge Infections after Autologous Stem Cell Transplantation.","authors":"Damian Mikulski, Kacper Kościelny, Izabela Dróżdż, Mateusz Nowicki, Małgorzata Misiewicz, Ewelina Perdas, Piotr Strzałka, Agnieszka Wierzbowska, Wojciech Fendler","doi":"10.3947/ic.2024.0021","DOIUrl":"10.3947/ic.2024.0021","url":null,"abstract":"<p><strong>Background: </strong>Autologous hematopoietic stem cell transplantation (AHSCT) is currently the backbone of the treatment of multiple myeloma (MM) and relapsed and refractory lymphomas. Notably, infections contribute to over 25% of fatalities among AHSCT recipients within the initial 100 days following the procedure. In this study, we aimed to evaluate three selected miRNAs: hsa-miR-155-5p, hsa-miR-320c, and hsa-miR-361-3p, in identifying AHSCT recipients at high risk of infectious events up to 100 days post-transplantation after discharge.</p><p><strong>Materials and methods: </strong>The study group consisted of 58 patients (43 with MM, 15 with lymphoma) treated with AHSCT. Blood samples were collected from all patients at the same time point: on day +14 after transplantation.</p><p><strong>Results: </strong>Fifteen patients (25.9%) experienced infectious complications after post-transplant discharge within the initial +100 days post-transplantation. The median time to infection onset was 44 days (interquartile range, 25-78). Four patients required hospitalization due to severe infection. High expression of hsa-miR-361-3p (fold change [FC], 1.79; <i>P</i>=0.0139) in the patients experiencing infectious complications and overexpression of hsa-miR-320c (FC, 2.14; <i>P</i><0.0001) in patients requiring hospitalization were observed. In the multivariate model, both lymphoma diagnosis (odds ratio [OR], 6.88; 95% confidence interval [CI], 1.55-30.56; <i>P</i>=0.0112) and high expression of hsa-miR-361-3p (OR, 3.00; 95% CI, 1.40-6.41; <i>P</i>=0.0047) were independent factors associated with post-discharge infectious complications occurrence. Our model in 10-fold cross-validation preserved its diagnostic potential with an area under the receiver operating characteristic curve of 0.78 (95% CI, 0.64-0.92).</p><p><strong>Conclusion: </strong>Elevated serum hsa-miR-361-3p emerges as a promising biomarker for identifying patients at risk of infection during the early post-discharge period, potentially offering optimization of the prophylactic use of antimicrobial agents tailored to the specific risk profile of each AHSCT recipient.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"339-350"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11458496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141890842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}